---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-318400"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T13:38:50.244359+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioMarin CAO Andrea Acosta resigns; CFO Mueller to serve as interim principal accounting officer

## Summary
- Andrea Acosta, Group VP and CAO, resigns effective Jan 28, 2022 to pursue another career opportunity.
- Company will search for a successor; if none appointed by Jan 28, CFO Brian Mueller will serve as principal accounting officer.
- Mueller will continue as CFO with no adjustment to compensation for additional duties.
- Mueller's bio previously disclosed in 2021 proxy; no related party transactions reported.

## SEC filing metadata
- accession: 0001193125-21-318400
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312521318400/0001193125-21-318400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312521318400/d106684d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-318400
- JSON: https://secwatch.observer/filing/0001193125-21-318400.json
- Plain text: https://secwatch.observer/filing/0001193125-21-318400.txt

## Key facts
- Executive change
  Andrea Acosta resigned as Group Vice President, Chief Accounting Officer, and principal accounting officer at BIOMARIN PHARMACEUTICAL INC.
  - Action: resigned
  - Role: Group Vice President, Chief Accounting Officer, and principal accounting officer
  source text: On October 29, 2021, Andrea Acosta, the Group Vice President, Chief Accounting Officer, and principal accounting officer of BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) notified BioMarin of her decision to resign, effective as of January 28, 2022 (the “Effective Date”), in order to pursue another career opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312521318400/0001193125-21-318400-index.htm
- Executive change
  Brian Mueller was appointed as principal accounting officer at BIOMARIN PHARMACEUTICAL INC.
  - Action: appointed
  - Role: principal accounting officer
  source text: In the event that the Company has not appointed a successor on or prior to the Effective Date, Brian Mueller, BioMarin’s Executive Vice President, Finance and Chief Financial Officer, will serve as the Company’s principal accounting officer from the Effective Date until Ms. Acosta’s successor is appointed.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312521318400/0001193125-21-318400-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.